Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially those ...

It’s the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.

Ascentage Pharma reported 2024 sales of $134.3M, up 342% YoY, driven by a $100M option payment from Takeda under an exclusive agreement. JP Morgan initiated Ascentage Pharma with an Overweight rating ...

Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the ...

A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's ...

July 25 (Reuters) - Danaher Corp (DHR.N), opens new tab on Tuesday cut its annual sales growth forecast for a second straight quarter, signaling that funding crunch in the drug development market was ...

Editorial Note: Blueprint may earn a commission from affiliate partner links featured here on our site. This commission does not influence our editors' opinions or evaluations. Please view our full ...